FDA: early efforts to prepare new drug labels 'not as good as we'd hoped'

Share this article:
"Not as good as we'd hoped" is the reaction by the FDA to early efforts by manufacturers to prepare Rx drug labels in conformance with the agency's new "content and format" requirements, in effect since publication of a final rule on the subject last summer.
Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.